“`html
Monte Rosa Therapeutics Inc (GLUE) shares recently exceeded the average analyst 12-month target price of $17.20, trading at $17.26 per share. This movement prompts analysts to reconsider their target price, with current projections ranging from $13.00 to $20.00, and a standard deviation of $2.774.
There are five analysts contributing to the target price average, and the latest ratings indicate seven strong buy ratings and two hold ratings, with an average rating of 1.44 (1 being strong buy and 5 being strong sell). Investor sentiment may shift based on the new trading price and resulting analyst evaluations.
“`
